

Form PTO-1595 (Rev. 0705)  
OMB No. 0651-0027 (Exp. 06/30/2008)

U.S. Department of Commerce  
United States Patent and Trademark Office

## RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

### 1. Name of Conveying Party(ies)

Biovail Laboratories International SRL

Additional name(s) of conveying party(ies) attached?  Yes  No

### 3. Nature of Conveyance/Execution Date(s):

Execution Date(s) 09/30/2006

- |                                     |  |                          |                |
|-------------------------------------|--|--------------------------|----------------|
| <input checked="" type="checkbox"/> | Assignment                                 | <input type="checkbox"/> | Merger         |
| <input type="checkbox"/>            | Security Agreement                         | <input type="checkbox"/> | Change of Name |
| <input type="checkbox"/>            | Joint Research Agreement                   |                          |                |
| <input type="checkbox"/>            | Government Interest Assignment             |                          |                |
| <input type="checkbox"/>            | Executive Order 9424, Confirmatory License |                          |                |
| <input type="checkbox"/>            | Other                                      |                          |                |

### 2. Name and Address of Receiving Party(ies)

Name: Circ Pharma Research and Development Limited

Internal Address: \_\_\_\_\_

45 Fitzwilliam Square

Street Address: \_\_\_\_\_

City: Dublin 2

State: \_\_\_\_\_

Country: Ireland Zip \_\_\_\_\_

Additional name(s) & Address(es) attached

### 4. Application or Patent Number(s):

A. Patent Application Number(s)

<u>09/488,103</u>	<u>10/214,345</u>
<u>10/814,293</u>	<u>10/339,487</u>
<u>08/797,318</u>	<u>10/205,028</u>
<u>10/420,944</u>	<u>10/653,415</u>
<u>10/653,469</u>	

Additional numbers attached?  Yes  No

This document is being filed together with a new application

B. Patent Number(s)

### 5. Name and Address to whom correspondence concerning document should be mailed:

Name: Marilou Watson, Esquire  
Synnestvedt & Lechner LLP

Internal Address: Suite 2600

Street Address: 1101 Market Street

City: Philadelphia

State: PA

Phone Number: 215-923-4466

Fax Number: 215-923-2189

Email Address: MWatson@synnlech.com

6. Total number of applications & patents involved: 8

7. Total Fee (37 CFR 1.21(h) & 3.41) \$ 360.00

- |                                     |   |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | Authorized to be charged by credit card             |
| <input type="checkbox"/>            | Authorized to be charged to deposit account         |
| <input type="checkbox"/>            | Enclosed  |
| <input type="checkbox"/>            | None required (government int. not affecting title) |


### 8. Payment Information

a. Credit Card Last 4 Numbers 1148  
Expiration Date 07/2010

Authorized User Name Jimmie D. Johnson

b. Deposit Account Number 19-5425

### 9. Signature:

  
Signature

Jimmie Johnson  
Name of Person Signing

5/16/07  
Date

Total number of pages including cover sheet, attachments, and documents

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to Mail Stop Assignment Recordation Services, Director of the USPTO, P. O. Box 1450, Alexandria, VA 22313-1450

700325299

REEL: 019306 FRAME: 0163

## PATENT ASSIGNMENT

WHEREAS, Biovail Laboratories International SRL (successor-in-interest of Biovail Laboratories Incorporated "BLI"), a Barbados society with restricted liability, whose head office is Chelston Park Building 2, Collymore Rock, St. Michael, BB14018 Barbados, West Indies ("ASSIGNOR") is the owner of U.S. patent/patent application rights and associated foreign patent/patent application rights (the "Patent Rights") recited in the attached Exhibit, which correspond to those rights identified in the definition of 'Product Patents' in the Athpharma Limited and Biovail Laboratories International SRL Asset Transfer, Termination and Rights Restructuring Agreement (the "Agreement") dated 20<sup>th</sup> day of July 2006.

WHEREAS the rights and obligations of Athpharma Limited pursuant to the Agreement have been transferred to Circ Pharma Research and Development Limited. Circ Pharma Research and Development Limited a corporation organized under the laws of Ireland and having its principal place of business at 45 Fitzwilliam Square, Dublin 2, Ireland ("ASSIGNEE"), is desirous of securing the entire right, title, and interest in and to said Patent Rights, the Inventions disclosed in said applications and patents comprising or constituting said Patent Rights, and in and to any Patent Rights that may be hereinafter granted thereon in any and all countries foreign thereto.

NOW THEREFORE, be it known that for and in partial consideration for the purchase price set forth in the Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR assigns and transfers to the ASSIGNEE, and the ASSIGNEE's successors and assigns, and the ASSIGNEE accepts, subject to the conditions of the Agreement, such assignment and transfer, an undivided right, title and interest in and to the Patent Rights, said Patent Rights to be held and enjoyed by the

above-named ASSIGNEE, for ASSIGNEE's own use and benefit, and for ASSIGNEE's successors and assigns to the full end of the term or terms for which said Patent Rights may be granted, subject only to the conditions of the Agreement.

Interested parties who acquire title, rights or grants to the Patent Rights are hereby notified that certain restrictions and obligations set forth in the Agreement have been made appurtenant to and run with the Patent Rights and such interested parties are on notice of such restrictions and obligations.

Further, ASSIGNOR hereby agrees to sign all lawful papers, execute all divisional, continuation, renewal, reexamination and reissue applications, and to execute all necessary assignment papers to cause any and all of said other Patent Rights to be issued to said ASSIGNEE, and to make all rightful oaths and generally do everything reasonably possible to aid said ASSIGNEE and its representatives to obtain proper protection for said Patent Rights in the U.S. and in any and all countries foreign thereto.

ASSIGNOR further agrees that the terms, covenants and conditions of this Assignment shall inure to the benefit of ASSIGNEE, its successors and assigns, and legal representatives, and shall be binding on ASSIGNOR, its legal representatives and assigns.

IN TESTIMONY WHEREOF, We have hereunto set our hands.

BIOVAIL LABORATORIES INTERNATIONAL SRL,


By: 

Name: MITCHELL CHARWARD

Title: C.O.O.

Date: <sup>H</sup> 30 September, 2006

CIRC PHARMA RESEARCH AND DEVELOPMENT LIMITED

By: 

Name: JIMMY SHEEHAN / SEANUS MULLIGAN

Title: DIRECTORS

Date: <sup>H</sup> 30 September, 2006

## EXHIBIT: Patent Rights

Country	Title	Application Number
Australia	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	2003201735
Australia	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	2003267756
Canada	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	2,473,106
Canada	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	2,497,896
European Procedure (Patents)	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	3700436.3
European Procedure (Patents)	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	3748451.6
Israel	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	162937
Israel	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	166773
Japan	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	2003-557553
Japan	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	2004533791
Mexico	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	PA/a/2004/006780
Mexico	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	PA/a/2005/002095
Norway	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	20050933

<b>Country</b>	<b>Title</b>	<b>Application Number</b>
New Zealand	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	534641
New Zealand	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	539173
Poland	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	P-375712
United States of America	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	11/205028
United States of America	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	10/339,487
United States of America	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	10/653,415
United States of America	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	60/347,775
United States of America	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	60/407,269
International Procedure	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	PCT/IB03/00336
International Procedure	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	PCT/IB2003/004523
South Africa	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	2004/5547
South Africa	PRAVASTATIN PHARMACEUTICAL FORMULATIONS AND METHODS OF THEIR USE	200501507
Australia	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	2003263556
Canada	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	2,497,832

Country	Title	Application Number
European Procedure (Patents)	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	3794018.6
Israel	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	166772
Japan	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	2004533786
Mexico	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	PA/a/2005/002074
Norway	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	20050840
New Zealand	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	539172
Poland	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	P-375411
United States of America	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	10/653,469
United States of America	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	60/407,270
International Procedure	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	PCT/IB2003/004361
South Africa	PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATIN DRUGS	200501508
Australia	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	2003263515
Canada	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	2495071
European Procedure (Patents)	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	3784442

Country	Title	Application Number
Israel	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	166299
Japan	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	2004-527255
Mexico	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	2005001559
Norway	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	20050786
New Zealand	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	537820
Poland	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	P375274
United States of America	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	10/214345
International Procedure	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	PCT/IB2003/004245
South Africa	ISOSORBIDE MONONITRATE COMPOSITIONS AND METHODS OF THEIR USE	2005/0778
Australia	MULTIPARTICULATE BISOPROLOL FORMULATION	<i>Validated</i>
Canada	MULTIPARTICULATE BISOPROLOL FORMULATION	2359709
Germany	MULTIPARTICULATE BISOPROLOL FORMULATION	<i>Validated</i>
European Procedure (Patents)	MULTIPARTICULATE BISOPROLOL FORMULATION	900786.5
Spain	MULTIPARTICULATE BISOPROLOL FORMULATION	<i>Validated</i>
France	MULTIPARTICULATE BISOPROLOL FORMULATION	<i>Validated</i>
United Kingdom	MULTIPARTICULATE BISOPROLOL FORMULATION	<i>Validated</i>



<b>Country</b>	<b>Title</b>	<b>Application Number</b>
Ireland	MULTIPARTICULATE BISOPROLOL FORMULATION	<i>Validated</i>
Italy	MULTIPARTICULATE BISOPROLOL FORMULATION	<i>Validated</i>
Japan	MULTIPARTICULATE BISOPROLOL FORMULATION	2000-594455
United States of America	MULTIPARTICULATE BISOPROLOL FORMULATION	10/814293
United States of America	MULTIPARTICULATE BISOPROLOL FORMULATION	09/488103
United States of America	MULTIPARTICULATE BISOPROLOL FORMULATION	60/116819
International Procedure	MULTIPARTICULATE BISOPROLOL FORMULATION	PCT/IE00/00005
United States of America	PHARMACEUTICAL FORMULATIONS FOR PREVENTING DRUG TOLERANCE	08/797318
United States of America	PHARMACEUTICAL FORMULATIONS FOR PREVENTING DRUG TOLERANCE	10/420944
United States of America	PHARMACEUTICAL FORMULATIONS FOR PREVENTING DRUG TOLERANCE	07/273217